Neovascular (Wet) Age-related Macular Degeneration Clinical Trial
Official title:
Observation of Treatment Patterns With Lucentis® (Ranibizumab) in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
The prospective observation period per patient will be up to 24 months. A minimum of one follow-up visit per year is required in order to maintain patient's participation in the study. The baseline visit will be used to assess eligibility and collect baseline characteristics information. The follow-up visits will take place at a frequency defined as per investigator's discretion. The study eye is defined as the first eye treated during the study, the other eye will be considered as the fellow eye. If both eyes are treated at baseline, the right eye will be chosen as the study eye. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04126317 -
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT06184360 -
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
||
| Active, not recruiting |
NCT05439629 -
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
|
Phase 3 | |
| Recruiting |
NCT05197270 -
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Terminated |
NCT05473715 -
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
|
Phase 4 | |
| Recruiting |
NCT06346600 -
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
|